Immunotherapy and More: The Top 10 Posts of 2017

While Cancer Research Catalyst covers the spectrum of cancer research news, we weren’t surprised to discover that the hottest topic on the blog this past year was immunotherapy.

It was certainly an exciting year for immunotherapy. In May, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) for use based on the presence of certain biomarkers rather than the site of origin of the tumor. Later in the year, the FDA approved two types of chimeric antigen receptor (CAR) T-cell therapy. Several immunotherapeutics received expanded approval, allowing patients with more types of cancer access to these potentially lifesaving treatments.

However, researchers are still striving to learn more about immunotherapy, exploring potential combination therapies and seeking biomarkers to predict which patients are the most likely to benefit from these treatments. That quest was at the heart of several of our most popular blog posts in 2017.

We’d love to know what you’d like to read more of in 2018. In the meantime, here are the Top 10 Cancer Research Catalyst blog posts of 2017, based on the number of page views:

Can We Treat Colorectal Cancer With Immunotherapy?

Experts Forecast Cancer Research and Treatment Advances in 2017

Lessons Learned From Combining Anti-OX40 and Anti-PD1 Immunotherapies

AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types

How Cancers Lose Something to Gain Immunotherapy Resistance

AACR Blog Turns 3: Check Out Our Top 10 Posts

FDA Approves First Liquid Biopsy Test for Lung Cancer Patients

Experts Forecast Cancer Research and Treatment Advances in 2016

Second CAR T-cell Therapy Approved by the FDA

Can a Serum Biomarker Predict Response to Immunotherapy?


Share this:

Leave a Reply